
Roche shutters most trials of Alzheimer’s drug after failed trials
By Julie Steenhuysen CHICAGO (Reuters) – Swiss drugmaker Roche is closing down most clinical trials...
1st December, 2022

By Julie Steenhuysen CHICAGO (Reuters) – Swiss drugmaker Roche is closing down most clinical trials...
1st December, 2022

By Deena Beasley SAN FRANCISCO (Reuters) -An experimental Alzheimer’s drug from Eisai and Biogen slo...
30th November, 2022

By Will Dunham WASHINGTON (Reuters) – Most galaxies are built around humongous black holes. While ma...
24th November, 2022

BERLIN (Reuters) – The German residential property market faces a growing risk of price corrections,...
23rd November, 2022

(Reuters) -Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot...
18th November, 2022

Interview Q&A with Annalie Davies, Partner in Financial Services at Heidrick & Struggles Australia W...
15th November, 2022

PXYZ invests further into proving relationship between attention and brand outcomes London, UK – 15t...
15th November, 2022

By Mike Dean, Managing Director, WhisperClaims, Accountancy firms are increasingly recognising the s...
10th November, 2022

The major challenge for organisations in overcoming age unconscious bias in the workplace is they ex...
4th November, 2022

By Hans Tesselaar, Executive Director, Banking Industry Architecture Network (BIAN) and Shanker Rama...
4th November, 2022

BERLIN (Reuters) – Scientists in Germany are working on ways to restore seagrass fields in the Balti...
1st November, 2022

By Tony Lysak, CEO at SkillsNow A recent report from Virgin Media O2 has revealed that the UK’s digi...
27th October, 2022